Tag: intravascular lithotripsy
FastWave Medical announces third utility patent for intravascular lithotripsy technology
FastWave Medical, a clinical-stage medical device company developing intravascular lithotripsy (IVL) technology, has announced the issuance of its third utility patent by the United...
AVS’s pulsatile IVL technology attracts an additional US$8.8 million to close...
AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its pulsatile intravascular lithotripsy (PIVL) therapy, has...
Shockwave Medical announces US launch of new peripheral IVL catheter
Shockwave Medical today announced the full US commercial availability of the Shockwave L6 peripheral intravascular lithotripsy (IVL) catheter following clearance by the US Food...
Funding secured to advance development of Pulse IVL system
AVS has announced that it raised US$20 million in Series B financing, which the company says will accelerate clinical trial timelines for its device...
Shockwave Medical and Genesis MedTech obtain regulatory approval in China for...
Shockwave Medical and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and...
Shockwave IVL maintains superiority to angioplasty in calcified peripheral disease at...
Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to...
Shockwave Medical announces global launch of new peripheral IVL catheter
Shockwave Medical has announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both CE mark and US...
Shockwave Medical enrols first patient in Disrupt BTK II study for...
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the...
CMS increases hospital outpatient payment for peripheral intravascular lithotripsy
Shockwave Medical has announced that, as part of the calendar year 2022 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for...
VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...
DISRUPT PAD III: Intravascular lithotripsy superior to PTA in acute procedural...
The DISRUPT PAD III randomised controlled trial (RCT) provides the largest level one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William...
Shockwave Medical announces that CMS has created new codes for intravascular...
Shockwave Medical announced today that the Centers for Medicare & Medicaid Services (CMS) has issued new codes for intravascular lithotripsy (IVL) procedures performed in...
IVL has “changed the dynamics” of facilitating EVAR & TEVAR in...
Frank Arko (Charlotte, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA), about the benefits of using Shockwave Intravascular Lithotripsy (IVL) when performing EVAR...
Shockwave IVL can aid in eliminating recoil and dissection during below-the-knee...
George Adams (Raleigh, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA) about the benefits of using easy-to-use Shockwave IVL (Intravascular Lithotripsy) in calcified...
Novel approach in treating stenotic peripheral arteries shown to be safe...
Twelve-month data prove that intravascular lithotripsy; a novel approach using pulsatile sonic pressure waves to modify intimal and medium calcium in stenotic peripheral arteries,...
“Fantastic” live case demonstrates potential value of intravascular lithotripsy
In an exciting session at the Charing Cross Symposium (CX; 24-27 April, London, UK), the audience witnessed the demonstration of a novel treatment strategy...
